Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01JCN4GW9GA2D5DC4XV9JCGAZH> ?p ?o. }
Showing items 1 to 34 of
34
with 100 items per page.
- 01JCN4GW9GA2D5DC4XV9JCGAZH classification A2.
- 01JCN4GW9GA2D5DC4XV9JCGAZH date "2024".
- 01JCN4GW9GA2D5DC4XV9JCGAZH language "eng".
- 01JCN4GW9GA2D5DC4XV9JCGAZH type journalArticle.
- 01JCN4GW9GA2D5DC4XV9JCGAZH hasPart 01JENS0QSTXASV0W95A7M4XRF4.pdf.
- 01JCN4GW9GA2D5DC4XV9JCGAZH subject "Medicine and Health Sciences".
- 01JCN4GW9GA2D5DC4XV9JCGAZH doi "10.3389/falgy.2024.1484931".
- 01JCN4GW9GA2D5DC4XV9JCGAZH issn "2673-6101".
- 01JCN4GW9GA2D5DC4XV9JCGAZH volume "5".
- 01JCN4GW9GA2D5DC4XV9JCGAZH abstract "Context Recent insights into type 2 inflammation have led to the development of monoclonal antibody therapies for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Despite add-on therapy with a monoclonal antibody, some individuals remain uncontrolled in terms of upper and/or lower airway symptoms, prompting an exploration of the efficacy of combining biological therapies and their impact on inflammatory pathways.Objectives In this article, we present a distinctive case of a patient with CRSwNP, severe eosinophilic asthma, and uncontrolled upper airway symptoms, who experienced substantial clinical and local inflammatory improvements through dual monoclonal antibody therapy.Methods We provide a detailed case description and analysis of the patient's nasal tissue and secretions to gain insights into the local nasal inflammation under this unique therapeutic approach.Results The addition of an anti-IL-4R alpha antibody led to an improvement in upper airway symptoms and a reduction in both eosinophilic and neutrophilic inflammation, despite prior anti-IL-5 therapy. These effects were consistently observed in both polyp tissue and nasal secretions.Conclusion Our patient, with CRSwNP, severe eosinophilic asthma, and uncontrolled upper airway symptoms, experienced substantial improvement with dual monoclonal antibody therapy, without major complications or side effects.".
- 01JCN4GW9GA2D5DC4XV9JCGAZH author 00EAA61A-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author 03488166-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author 0695fdc3-38e0-11eb-9f20-a6eb2bc6bf30.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author 14561F7E-4BA1-11E6-B5AC-0417B5D1D7B1.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author 3493B150-F0EE-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author 5de0ffe1-c99a-11ec-a040-bc94ebe6b5df.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author 70BEB176-786B-11E6-815E-A870B5D1D7B1.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author F497BC5E-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author F52558D4-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author F58DCC8E-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author F661F0B8-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author F668DE28-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH author F946B58E-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JCN4GW9GA2D5DC4XV9JCGAZH dateCreated "2024-11-14T10:46:50Z".
- 01JCN4GW9GA2D5DC4XV9JCGAZH dateModified "2025-02-25T12:26:35Z".
- 01JCN4GW9GA2D5DC4XV9JCGAZH name "Case report : dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma : a proteome analysis".
- 01JCN4GW9GA2D5DC4XV9JCGAZH pagination urn:uuid:e4359355-e82c-4360-82c8-069a5bca2073.
- 01JCN4GW9GA2D5DC4XV9JCGAZH sameAs LU-01JCN4GW9GA2D5DC4XV9JCGAZH.
- 01JCN4GW9GA2D5DC4XV9JCGAZH sourceOrganization urn:uuid:0bf9e564-b48f-4237-ac01-f4ab9312b965.
- 01JCN4GW9GA2D5DC4XV9JCGAZH sourceOrganization urn:uuid:23fb83dc-c85c-41a0-b640-3b4c2d355e58.
- 01JCN4GW9GA2D5DC4XV9JCGAZH sourceOrganization urn:uuid:4fb99169-4459-4db3-b100-0d6291f13da9.
- 01JCN4GW9GA2D5DC4XV9JCGAZH sourceOrganization urn:uuid:f4591b7f-7a8c-4dfb-99c2-b455369c1873.
- 01JCN4GW9GA2D5DC4XV9JCGAZH sourceOrganization urn:uuid:fff4d4ac-e9b1-4210-b5cc-e6dceccb6f69.
- 01JCN4GW9GA2D5DC4XV9JCGAZH type A2.